Lead Product(s): BEN-2293
Therapeutic Area: Dermatology Product Name: BEN-2293
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 11, 2021
BEN-2293 is a selective Pan-Trk antagonist formulated for topical delivery, with a pharmacokinetic profile designed for low systemic exposure to deliver the optimal safety and efficacy profile in the treatment of itch and inflammation associated with Atopic Dermatitis.